GlassScriptPhysician profile
Thomas Amankonah
NPI 1780762534
$10,169.45
in general payments reported to CMS, 2019-2025
7 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $259 · 2021: $8,423 · 2022: $55.99 · 2024: $122 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $9,057.31 | 2019-2025 | |
| Boston Scientific Corporation | $556.27 | 2019-2020 | |
| Abbvie INC. | $349.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.87 | 2019 | |
| Intercept Pharmaceuticals, INC. | $99.85 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Amankonah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.